Retatrutide Is One Click Away. That Doesn’t Make it Safe.

A few clicks, a credit card, and a package arrives at your door. The same technology that has expanded access to information and consumer goods has also made it easier than ever for unregulated products to reach consumers while masquerading as legitimate medicine.
As an endocrinologist who treats obesity and diabetes, I have watched new therapies transform care for a complex chronic disease. I also regularly have patients asking about products they found online, on social media, at a medical spa, or through friends and family. Their curiosity and desire for affordable treatment options make sense. But their safety depends on knowing what a product actually is, and whether it has been tested to the standards we expect of any medicine.
Those standards exist for good reason. Before a complex medication reaches patients, it goes through years of laboratory research and progressively larger clinical trials that establish whether it works, for which patients, at what dose, and with what risks. It is then produced by an approved manufacturer under strict quality controls, in facilities subject to inspection, and monitored for safety after it reaches the market. This system allows a physician to safely prescribe a drug for a specific condition, and a patient to trust what is in their syringe.
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) went through that process and were approved by FDA. But products sold online or at medical spas using the same ingredient names, semaglutide and tirzepatide, do not automatically carry the same safeguards.
Their success has fueled excitement about what comes next.
Retatrutide, often marketed online as “Reta” or “GLP-3,” is the latest example. (Side note: the nickname is a misnomer. The molecule acts on three hormone receptors — GLP-1, GIP, and glucagon — making it more accurately a “triple-G” agonist.) Results from phase 3 clinical trials in obesity and type 2 diabetes were recently presented at the European Association for the Study of Diabetes meeting in Milan, with simultaneous publication in the New England Journal of Medicine and The Lancet. The results are impressive, but retatrutide remains investigational and is not approved for any use.
Just as important, the retatrutide studied in those trials is not what is being sold online. Clinical trial participants receive drugs made to exacting specifications, at carefully defined doses and escalation schedules, under close medical monitoring. A gray-market vial labeled “retatrutide” may or may not contain the actual molecule. It may contain more or less than the label claims, or impurities and contaminants no one has tested for. And because there is no established dose for a product of unknown content, buyers are left to mix and inject based on guesswork from online forums. Promising data on the real drug tell us little about what is in that gray-market vial.

The FDA’s position is explicit: federal law does not permit retatrutide to be compounded or sold. The agency notes that retatrutide is not an ingredient in any FDA-approved drug and has not been shown to be safe and effective for any condition. Calling a product “compounded retatrutide” does not make it an approved or lawful treatment, and a “for research use only” label does not make it safe. The FDA urges consumers not to buy these products, warning that their quality is unknown and they may harm patients’ health.
The agency has also taken enforcement action. In a March 2026 warning letter to Gram Peptides, FDA identified products marketed as retatrutide as unapproved new drugs and said introducing them into interstate commerce violated federal law. It warned that injectables can cause serious harm because they bypass the body’s key defenses against toxins and microorganisms. No professional-looking website or glowing testimonial can confirm a product’s identity, strength, purity, or sterility.
We, as clinicians, must help patients navigate this landscape without judgment. We need to create a space where patients feel comfortable bringing advertisements and questions into the exam room, where we can review the evidence together and address access issues.
My advice to my patients is clear: do not buy or use retatrutide until it is FDA approved and available from the legitimate manufacturer. In the meantime, I encourage them to ask me or another provider which FDA-approved treatments may fit their needs and how to obtain them through a licensed pharmacy. If investigational treatments interest them, I encourage them to ask about legitimate clinical trials.
Technology can support informed healthcare decisions, but it cannot replace medical guidance. The next step toward better health should begin with a patient-doctor conversation — not an online checkout.